Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083551 · ClinicalTrials.gov registry record · Phase 3
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
A Phase 3 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 668
- Enrollment target
NCT00083551: Completed Phase 3 study, sponsored by University of Arkansas.
NCT00083551 is a Phase 3 study that has completed, run by University of Arkansas. The registered enrollment target is 668 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083551, a Phase 3 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 668 participants
- Enrollment target
Study Summary
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
Primary Outcome
Overall Survival at six years after initiating protocol therapy
Interventions
- DRUG Cisplatin
- DRUG Cytoxan
- DRUG BCNU
- DRUG Thalidomide
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 668 participants |
| Start Date | 1998-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
What the finished NCT00083551 record still lists
NCT00083551 is an interventional study that assigns participants to a tested intervention. The registered 668 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00083551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083551 about?
NCT00083551 is a clinical study titled "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy". This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
What is the current status of trial NCT00083551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 668 participants. The study started on 1998-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00083551?
The interventions under investigation include: Cisplatin (DRUG), Cytoxan (DRUG), BCNU (DRUG), Thalidomide (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00083551?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00083551's enrollment target sits among peer trials
668 548th of 2000 higher than 1,450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
- NCT04179981 · 668 participants · NA
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
- NCT05006482 · 668 participants · Phase 3
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- NCT02984761 · 670 participants · NA
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia